Trading Services

The Smart Cap Alert’s focus is putting probability squarely in your favor. Editor Karim Rahemtulla solely tracks opportunities with high likelihoods of success, which most times translates into a 90%-plus win rate. Karim achieves such incredible outcomes by 1) capitalizing on the market’s intense volatility (borne out of the increase in “Black Swan” events), and 2) using a strategy that let’s you own some of the biggest (and best) companies in the world for a fraction of the price of actual shares. Sounds hard to believe, but Karim consistently buys companies like Apple, Google and Goldman Sachs for pennies on the dollar. Such a strategy not only produces consistent double- and triple-digit gains, but is also largely insulated from market downturns.

The Instant Money Trader is perhaps our most innovative trading service. Using strategies and techniques he perfected as a floor trader on The New York Mercantile Exchange, Lee Lowell recommends easy-to-make trades that deposit cash into your trading account, immediately. Lee’s instant cash payouts range anywhere from a few hundred dollars to over a thousand. And you can earn this cash without ever buying shares of stock. Better yet, the cash is yours to use any way you see fit. No strings attached. The strategy is simple and much safer than most investors imagine, as long as you stick exclusively to Lee’s recommendations.

FastCap editor, Matthew Weinschenk, is one of the few people in the world capable of accurately applying the “Post Earnings Drift” (PED) phenomenon for profits. When applied correctly, the PED equation governs stock movements very much like the laws governing time and space. In a recent three-week period – under the watchful eye of analysts – the PED equation yielded significantly favorable results.

Profits come hard and fast when breakthrough drugs are involved. That’s why First Access is positioned exclusively for stock gains within the lucrative biotech/healthcare space. First Access editor, Marc Lichtenfeld, is wholly entrenched in the industry. His contacts – oftentimes CEOs of major biotech/pharmaceutical companies – give him the razor-sharp edge it takes to make consistently profitable trades.